Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB26FX1KU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,012
Award facts
- Contract value 100% obligated
- $26,011.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $26,012 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tecentriq (atezolizumab) 1,200 mg/20 mL vials. This delivery order, issued on October 31, 2025, with an ultimate completion date of November 24, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a critical supplier within the Department of Defense's pharmaceutical supply chain, specializing in the distribution of branded and generic prescription medications, biologics, and specialty pharmaceuticals to military healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for DoD healthcare operations. The parent contract, valued at $500 million with a completion date of December 31, 2036, authorizes DLA to issue multiple firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support recurring medical supply needs across military healthcare facilities worldwide. As one of multiple regional prime vendor contractors under this strategic acquisition vehicle, DMS Pharmaceutical Group has demonstrated substantial performance capability through consistent award activity since its registration in the federal system in 2001.
Quick answers
Who was awarded contract SPE2DB26FX1KU?
SPE2DB26FX1KU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 31, 2025.
How much is contract SPE2DB26FX1KU worth?
The government has obligated $26,012 on SPE2DB26FX1KU.
Is contract SPE2DB26FX1KU an order under another contract?
Yes. SPE2DB26FX1KU is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1KU competed?
The extent of competition for SPE2DB26FX1KU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award